Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2667)	1/14/2010 11:38:52 AM
From: Jibacoa	Respond to of 3722

OSTE has been up 17.28% with volume already > 209Ks which is > its ADV.<g> bigcharts.marketwatch.com It reported preliminary 4thQ results with revenues of $26.3M vs. 24.6M The 2009 revenue included $3.3M from an agreement to license certain of its tissue processing and is expected to contribute approximately $2.3M to 4thQ profits.(Albeit that is apparently an "accounting revenue", since the actual revenue will be gradually received in the next 3 yrs.<g>) OSTE also reported that it closed 2009 with approximately $10.7M in cash and that it obtained a $10M credit line in Dec., wich together with its cash, it expects to cover its expected expenses for the next Yr. <g> They sid that the MagniFuse Bone Graft has generated over $400,000 in revenue during the 4thQ, after its initial launch in October and some of its other products have continued to do well. In December they filed an NDA with the FDA for Duratech BioRegeneration Matrix, which they plan to launch in the U.S. in mid-2010. They plan to release final financial results for 2009 in late February. OSTE has 4Qs of lower revenues and higher losses and the EL for 2009 is around $0.34 vs. $0.12 on the black in 2008 <g> The stock has been trading around 0.7xBV Will see if it can make it back to the $4 level.<g> bigcharts.marketwatch.com Bernard